Cerebrospinal Fluid and Clinical Profiles in Adult Type 2-3 Spinal Muscular Atrophy Patients Treated with Nusinersen: An 18-Month Single-Centre Experience.
Journal
Clinical drug investigation
ISSN: 1179-1918
Titre abrégé: Clin Drug Investig
Pays: New Zealand
ID NLM: 9504817
Informations de publication
Date de publication:
Sep 2021
Sep 2021
Historique:
accepted:
27
07
2021
pubmed:
15
8
2021
medline:
1
9
2021
entrez:
14
8
2021
Statut:
ppublish
Résumé
Nusinersen was approved as the first disease-modifying therapy in spinal muscular atrophy (SMA). Our aim was to analyse therapy-related changes in cerebrospinal fluid (CSF) and serum parameters of adult type 2-3 SMA and to correlate biochemical data with motor functional status. Nine adult SMA type 2-3 patients and ten control subjects without neurodegenerative diseases were included in our single-centre study. Cross-sectional analysis of CSF routine parameters, CSF neurofilament light chain, CSF Tau, CSF phospho-Tau and serum creatinine was performed between SMA patients at baseline (T0) and control subjects. The above-mentioned fluid parameters were longitudinally analysed in the SMA cohort after loading dose (T1) and after four maintenance doses (T2, T3, T4, T5). Hammersmith Functional Motor Scale Expanded (HFMSE), Revised Upper Limb Module (RULM) and the 6-minute walking test (6MWT) were used to evaluate motor outcomes. Improvements in HFMSE, RULM and 6MWT were observed only after the loading dose of nusinersen. No significant differences in routine CSF parameters and CSF markers of neurodegeneration were found between SMA patients and control subjects. Serum creatinine levels were significantly lower in SMA patients than in control subjects. CSF/serum albumin ratio (Qalb) significantly increased from T0 to each time point, without any further increase after the maintenance doses. Persistent systemic oligoclonal bands (OCBs) were found in five patients from baseline. Three more patients developed persistent systemic OCBs from T1; one patient showed intrathecal OCBSs from baseline to T5. Markers of neurodegeneration did not change during the follow-up and did not correlate with motor scores at baseline and at each timepoint. Serum creatinine levels significantly correlated with HFMSE and RULM at each time point. The increase of the Qalb values and the development of systemic OCBs in some SMA patients could be due to repeated lumbar puncture and to the immunogenic effect of nusinersen. On the other hand, the presence of OCBs in serum and/or CSF at baseline should be further investigated. Furthermore, biomarkers of neurodegeneration did not play a prognostic role in our cohort of adult SMA patients.
Sections du résumé
BACKGROUND AND OBJECTIVES
OBJECTIVE
Nusinersen was approved as the first disease-modifying therapy in spinal muscular atrophy (SMA). Our aim was to analyse therapy-related changes in cerebrospinal fluid (CSF) and serum parameters of adult type 2-3 SMA and to correlate biochemical data with motor functional status.
METHODS
METHODS
Nine adult SMA type 2-3 patients and ten control subjects without neurodegenerative diseases were included in our single-centre study. Cross-sectional analysis of CSF routine parameters, CSF neurofilament light chain, CSF Tau, CSF phospho-Tau and serum creatinine was performed between SMA patients at baseline (T0) and control subjects. The above-mentioned fluid parameters were longitudinally analysed in the SMA cohort after loading dose (T1) and after four maintenance doses (T2, T3, T4, T5). Hammersmith Functional Motor Scale Expanded (HFMSE), Revised Upper Limb Module (RULM) and the 6-minute walking test (6MWT) were used to evaluate motor outcomes.
RESULTS
RESULTS
Improvements in HFMSE, RULM and 6MWT were observed only after the loading dose of nusinersen. No significant differences in routine CSF parameters and CSF markers of neurodegeneration were found between SMA patients and control subjects. Serum creatinine levels were significantly lower in SMA patients than in control subjects. CSF/serum albumin ratio (Qalb) significantly increased from T0 to each time point, without any further increase after the maintenance doses. Persistent systemic oligoclonal bands (OCBs) were found in five patients from baseline. Three more patients developed persistent systemic OCBs from T1; one patient showed intrathecal OCBSs from baseline to T5. Markers of neurodegeneration did not change during the follow-up and did not correlate with motor scores at baseline and at each timepoint. Serum creatinine levels significantly correlated with HFMSE and RULM at each time point.
CONCLUSIONS
CONCLUSIONS
The increase of the Qalb values and the development of systemic OCBs in some SMA patients could be due to repeated lumbar puncture and to the immunogenic effect of nusinersen. On the other hand, the presence of OCBs in serum and/or CSF at baseline should be further investigated. Furthermore, biomarkers of neurodegeneration did not play a prognostic role in our cohort of adult SMA patients.
Identifiants
pubmed: 34389971
doi: 10.1007/s40261-021-01071-0
pii: 10.1007/s40261-021-01071-0
pmc: PMC8390404
doi:
Substances chimiques
Oligonucleotides
0
nusinersen
5Z9SP3X666
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
775-784Informations de copyright
© 2021. The Author(s).
Références
Darras BT. Spinal muscular atrophies. Pediatr Clin N Am. 2015;62:743–66. https://doi.org/10.1016/j.pcl.2015.03.010 .
doi: 10.1016/j.pcl.2015.03.010
Kolb SJ, Coffey CS, Yankey JW, Krosschell K, Arnold WD, Rutkove SB, Swoboda KJ, Reyna SP, Sakonju A, Darras BT, et al. Natural history of infantile-onset spinal muscular atrophy. Ann Neurol. 2017;82:883–91. https://doi.org/10.1002/ana.25101 .
doi: 10.1002/ana.25101
pubmed: 29149772
pmcid: 5776712
Prior TW, Krainer AR, Hua Y, Swoboda KJ, Snyder PC, Bridgeman SJ, Burghes AHM, Kissel JT. A positive modifier of spinal muscular atrophy in the SMN2 gene. Am J Hum Genet. 2009;85:408–13. https://doi.org/10.1016/j.ajhg.2009.08.002 .
doi: 10.1016/j.ajhg.2009.08.002
pubmed: 19716110
pmcid: 2771537
Cuscó I, Bernal S, Blasco-Pérez L, Calucho M, Alias L, Fuentes-Prior P, Tizzano EF. Practical guidelines to manage discordant situations of SMN2 copy number in patients with spinal muscular atrophy. Neurol Genet. 2020;6: e530. https://doi.org/10.1212/NXG.0000000000000530 .
doi: 10.1212/NXG.0000000000000530
pubmed: 33324756
pmcid: 7713720
Mercuri E, Darras BT, Chiriboga CA, Day JW, Campbell C, Connolly AM, Iannaccone ST, Kirschner J, Kuntz NL, Saito K, et al. Nusinersen versus sham control in later-onset spinal muscular atrophy. N Engl J Med. 2018;378:625–35. https://doi.org/10.1056/NEJMoa1710504 .
doi: 10.1056/NEJMoa1710504
pubmed: 29443664
Finkel RS, Chiriboga CA, Vajsar J, Day JW, Montes J, De Vivo DC, Yamashita M, Rigo F, Hung G, Schneider E, et al. Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study. Lancet Lond Engl. 2016;388:3017–26. https://doi.org/10.1016/S0140-6736(16)31408-8 .
doi: 10.1016/S0140-6736(16)31408-8
Luu KT, Norris DA, Gunawan R, Henry S, Geary R, Wang Y. Population pharmacokinetics of nusinersen in the cerebral spinal fluid and plasma of pediatric patients with spinal muscular atrophy following intrathecal administrations. J Clin Pharmacol. 2017;57:1031–41. https://doi.org/10.1002/jcph.884 .
doi: 10.1002/jcph.884
pubmed: 28369979
Winter B, Guenther R, Ludolph AC, Hermann A, Otto M, Wurster CD. Neurofilaments and Tau in CSF in an infant with SMA type 1 treated with nusinersen. J Neurol Neurosurg Psychiatry. 2019;90:1068–9. https://doi.org/10.1136/jnnp-2018-320033 .
doi: 10.1136/jnnp-2018-320033
pubmed: 30630960
Olsson B, Alberg L, Cullen NC, Michael E, Wahlgren L, Kroksmark A-K, Rostasy K, Blennow K, Zetterberg H, Tulinius M. NFL is a marker of treatment response in children with SMA treated with nusinersen. J Neurol. 2019;266:2129–36. https://doi.org/10.1007/s00415-019-09389-8 .
doi: 10.1007/s00415-019-09389-8
pubmed: 31123861
pmcid: 6687695
Darras BT, Crawford TO, Finkel RS, Mercuri E, De Vivo DC, Oskoui M, Tizzano EF, Ryan MM, Muntoni F, Zhao G, et al. Neurofilament as a potential biomarker for spinal muscular atrophy. Ann Clin Transl Neurol. 2019;6:932–44. https://doi.org/10.1002/acn3.779 .
doi: 10.1002/acn3.779
pubmed: 31139691
pmcid: 6530526
Faravelli I, Meneri M, Saccomanno D, Velardo D, Abati E, Gagliardi D, Parente V, Petrozzi L, Ronchi D, Stocchetti N, et al. Nusinersen treatment and cerebrospinal fluid neurofilaments: an explorative study on spinal muscular atrophy type 3 patients. J Cell Mol Med. 2020;24:3034–9. https://doi.org/10.1111/jcmm.14939 .
doi: 10.1111/jcmm.14939
pubmed: 32032473
pmcid: 7077557
Wurster CD, Günther R, Steinacker P, Dreyhaupt J, Wollinsky K, Uzelac Z, Witzel S, Kocak T, Winter B, Koch JC, et al. Neurochemical markers in CSF of adolescent and adult SMA patients undergoing nusinersen treatment. Ther Adv Neurol Disord. 2019;12:1756286419846058. https://doi.org/10.1177/1756286419846058 .
doi: 10.1177/1756286419846058
pubmed: 31205491
pmcid: 6535708
Totzeck A, Stolte B, Kizina K, Bolz S, Schlag M, Thimm A, Kleinschnitz C, Hagenacker T. Neurofilament heavy chain and tau protein are not elevated in cerebrospinal fluid of adult patients with spinal muscular atrophy during loading with nusinersen. Int J Mol Sci. 2019. https://doi.org/10.3390/ijms20215397 .
doi: 10.3390/ijms20215397
pubmed: 31671515
pmcid: 6862027
Introna A, Milella G, D’Errico E, Fraddosio A, Scaglione G, Ucci M, Ruggieri M, Simone IL. Is cerebrospinal fluid amyloid-Β42 a promising biomarker of response to nusinersen in adult spinal muscular atrophy patients? Muscle Nerve. 2021. https://doi.org/10.1002/mus.27212 .
doi: 10.1002/mus.27212
pubmed: 33660868
pmcid: 8251706
Kessler T, Latzer P, Schmid D, Warnken U, Saffari A, Ziegler A, Kollmer J, Möhlenbruch M, Ulfert C, Herweh C, et al. Cerebrospinal fluid proteomic profiling in nusinersen-treated patients with spinal muscular atrophy. J Neurochem. 2020;153:650–61. https://doi.org/10.1111/jnc.14953 .
doi: 10.1111/jnc.14953
pubmed: 31903607
https://www.ema.europa.eu/en/medicines/human/EPAR/spinraza . Accessed 23 Jul 2021.
Mercuri E, Finkel RS, Muntoni F, Wirth B, Montes J, Main M, Mazzone ES, Vitale M, Snyder B, Quijano-Roy S, et al. Diagnosis and management of spinal muscular atrophy: part 1: recommendations for diagnosis, rehabilitation, orthopedic and nutritional care. Neuromuscul Disord NMD. 2018;28:103–15. https://doi.org/10.1016/j.nmd.2017.11.005 .
doi: 10.1016/j.nmd.2017.11.005
pubmed: 29290580
Vázquez-Costa JF, Povedano M, Nascimiento-Osorio AE, Escribano AM, Garcia SK, Dominguez R, Exposito JM, González L, Marco C, Castillo JM, et al. Validation of motor and functional scales for the evaluation of adult patients with 5q spinal muscular atrophy. medRxiv. 2021. https://doi.org/10.1101/2021.06.12.21258357 .
doi: 10.1101/2021.06.12.21258357
Hagenacker T, Wurster CD, Günther R, Schreiber-Katz O, Osmanovic A, Petri S, Weiler M, Ziegler A, Kuttler J, Koch JC, et al. Nusinersen in adults with 5q spinal muscular atrophy: a non-interventional, multicentre, observational cohort study. Lancet Neurol. 2020;19:317–25. https://doi.org/10.1016/S1474-4422(20)30037-5 .
doi: 10.1016/S1474-4422(20)30037-5
pubmed: 32199097
Maggi L, Bello L, Bonanno S, Govoni A, Caponnetto C, Passamano L, Grandis M, Trojsi F, Cerri F, Ferraro M, et al. Nusinersen safety and effects on motor function in adult spinal muscular atrophy type 2 and 3. J Neurol Neurosurg Psychiatry. 2020;91:1166–74. https://doi.org/10.1136/jnnp-2020-323822 .
doi: 10.1136/jnnp-2020-323822
pubmed: 32917822
Yeo CJJ, Simeone SD, Townsend EL, Zhang RZ, Swoboda KJ. Prospective cohort study of nusinersen treatment in adults with spinal muscular atrophy. J Neuromuscul Dis. 2020;7:257–68. https://doi.org/10.3233/JND-190453 .
doi: 10.3233/JND-190453
pubmed: 32333595
Morganti B, Scivoletto G, Ditunno P, Ditunno JF, Molinari M. Walking index for spinal cord injury (WISCI): criterion validation. Spinal Cord. 2005;43:27–33. https://doi.org/10.1038/sj.sc.3101658 .
doi: 10.1038/sj.sc.3101658
pubmed: 15520841
Dunaway Young S, Montes J, Kramer SS, Marra J, Salazar R, Cruz R, Chiriboga CA, Garber CE, De Vivo DC. Six-minute walk test is reliable and valid in spinal muscular atrophy. Muscle Nerve. 2016;54:836–42. https://doi.org/10.1002/mus.25120 .
doi: 10.1002/mus.25120
pubmed: 27015431
Tibbling G, Link H, Ohman S. Principles of Albumin and IgG Analyses in Neurological Disorders. I. Establishment of Reference Values. Scand J Clin Lab Invest. 1977;37:385–90. https://doi.org/10.1080/00365517709091496 .
doi: 10.1080/00365517709091496
pubmed: 337459
Reiber H. External quality assessment in clinical neurochemistry: survey of analysis for cerebrospinal fluid (CSF) proteins based on CSF/serum quotients. Clin Chem. 1995;41:256–63.
doi: 10.1093/clinchem/41.2.256
Andersson M, Alvarez-Cermeño J, Bernardi G, Cogato I, Fredman P, Frederiksen J, Fredrikson S, Gallo P, Grimaldi LM, Grønning M. Cerebrospinal fluid in the diagnosis of multiple sclerosis: a consensus report. J Neurol Neurosurg Psychiatry. 1994;57:897–902. https://doi.org/10.1136/jnnp.57.8.897 .
doi: 10.1136/jnnp.57.8.897
pubmed: 8057110
pmcid: 1073070
Reiber H. Cerebrospinal fluid-physiology, analysis and interpretation of protein patterns for diagnosis of neurological diseases. Mult Scler Houndmills Basingstoke Engl. 1998;4:99–107. https://doi.org/10.1177/135245859800400302 .
doi: 10.1177/135245859800400302
Goldstein ME, Sternberger NH, Sternberger LA. Phosphorylation protects neurofilaments against proteolysis. J Neuroimmunol. 1987;14:149–60. https://doi.org/10.1016/0165-5728(87)90049-x .
doi: 10.1016/0165-5728(87)90049-x
pubmed: 3029175
Tortelli R, Ruggieri M, Cortese R, D’Errico E, Capozzo R, Leo A, Mastrapasqua M, Zoccolella S, Leante R, Livrea P, et al. Elevated cerebrospinal fluid neurofilament light levels in patients with amyotrophic lateral sclerosis: a possible marker of disease severity and progression. Eur J Neurol. 2012;19:1561–7. https://doi.org/10.1111/j.1468-1331.2012.03777.x .
doi: 10.1111/j.1468-1331.2012.03777.x
pubmed: 22680408
Petzold A, Altintas A, Andreoni L, Bartos A, Berthele A, Blankenstein MA, Buee L, Castellazzi M, Cepok S, Comabella M, et al. Neurofilament ELISA validation. J Immunol Methods. 2010;352:23–31. https://doi.org/10.1016/j.jim.2009.09.014 .
doi: 10.1016/j.jim.2009.09.014
pubmed: 19857497
Scarafino A, D’Errico E, Introna A, Fraddosio A, Distaso E, Tempesta I, Morea A, Mastronardi A, Leante R, Ruggieri M, et al. Diagnostic and prognostic power of CSF Tau in amyotrophic lateral sclerosis. J Neurol. 2018;265:2353–62. https://doi.org/10.1007/s00415-018-9008-3 .
doi: 10.1007/s00415-018-9008-3
pubmed: 30116940
Paladino P, Valentino F, Piccoli T, Piccoli F, La Bella V. Cerebrospinal fluid tau protein is not a biological marker in amyotrophic lateral sclerosis. Eur J Neurol. 2009;16:257–61. https://doi.org/10.1111/j.1468-1331.2008.02405.x .
doi: 10.1111/j.1468-1331.2008.02405.x
pubmed: 19138331
Pijnenburg YAL, Verwey NA, van der Flier WM, Scheltens P, Teunissen CE. Discriminative and prognostic potential of cerebrospinal fluid PhosphoTau/Tau ratio and neurofilaments for frontotemporal dementia subtypes. Alzheimers Dement Amst Neth. 2015;1:505–12. https://doi.org/10.1016/j.dadm.2015.11.001 .
doi: 10.1016/j.dadm.2015.11.001
Walter MC, Wenninger S, Thiele S, Stauber J, Hiebeler M, Greckl E, Stahl K, Pechmann A, Lochmüller H, Kirschner J, et al. Safety and treatment effects of nusinersen in longstanding adult 5q-SMA type 3—a prospective observational study. J Neuromuscul Dis. 2019;6:453–65. https://doi.org/10.3233/JND-190416 .
doi: 10.3233/JND-190416
pubmed: 31594243
pmcid: 6918909
Wurster CD, Koch JC, Cordts I, Dreyhaupt J, Otto M, Uzelac Z, Witzel S, Winter B, Kocak T, Schocke M, et al. Routine cerebrospinal fluid (CSF) parameters in patients with spinal muscular atrophy (SMA) treated with nusinersen. Front Neurol. 2019. https://doi.org/10.3389/fneur.2019.01179 .
doi: 10.3389/fneur.2019.01179
pubmed: 31787927
pmcid: 6854024
Müschen LH, Osmanovic A, Binz C, Jendretzky KF, Ranxha G, Bronzlik P, Abu-Fares O, Wiehler F, Möhn N, Hümmert MW, et al. Cerebrospinal fluid parameters in antisense oligonucleotide-treated adult 5q-spinal muscular atrophy patients. Brain Sci. 2021. https://doi.org/10.3390/brainsci11030296 .
doi: 10.3390/brainsci11030296
pubmed: 34200087
pmcid: 8228206
Singh NN, Hoffman S, Reddi PP, Singh RN. Spinal muscular atrophy: broad disease spectrum and sex-specific phenotypes. Biochim Biophys Acta Mol Basis Dis. 2021;1867: 166063. https://doi.org/10.1016/j.bbadis.2020.166063 .
doi: 10.1016/j.bbadis.2020.166063
pubmed: 33412266
Shababi M, Habibi J, Yang HT, Vale SM, Sewell WA, Lorson CL. Cardiac defects contribute to the pathology of spinal muscular atrophy models. Hum Mol Genet. 2010;19:4059–71. https://doi.org/10.1093/hmg/ddq329 .
doi: 10.1093/hmg/ddq329
pubmed: 20696672
Khairallah M-T, Astroski J, Custer SK, Androphy EJ, Franklin CL, Lorson CL. SMN deficiency negatively impacts red pulp macrophages and spleen development in mouse models of spinal muscular atrophy. Hum Mol Genet. 2017;26:932–41. https://doi.org/10.1093/hmg/ddx008 .
doi: 10.1093/hmg/ddx008
pubmed: 28062667
pmcid: 6075362
Deguise M-O, Kothary R. New insights into SMA pathogenesis: immune dysfunction and neuroinflammation. Ann Clin Transl Neurol. 2017;4:522–30. https://doi.org/10.1002/acn3.423 .
doi: 10.1002/acn3.423
pubmed: 28695153
pmcid: 5497530
Wan B, Feng P, Guan Z, Sheng L, Liu Z, Hua Y. A severe mouse model of spinal muscular atrophy develops early systemic inflammation. Hum Mol Genet. 2018;27:4061–76. https://doi.org/10.1093/hmg/ddy300 .
doi: 10.1093/hmg/ddy300
pubmed: 30137324
Zeman A, McLean B, Keir G, Luxton R, Sharief M, Thompson E. The significance of serum oligoclonal bands in neurological diseases. J Neurol Neurosurg Psychiatry. 1993;56:32–5.
doi: 10.1136/jnnp.56.1.32
Gingele S, Hümmert MW, Alvermann S, Jendretzky KF, Bönig L, Brieskorn M, Schwenkenbecher P, Sühs K-W, Müschen LH, Osmanovic A, et al. Routine cerebrospinal fluid cytology reveals unique inclusions in macrophages during treatment with nusinersen. Front Neurol. 2019;10:735. https://doi.org/10.3389/fneur.2019.00735 .
doi: 10.3389/fneur.2019.00735
pubmed: 31354609
pmcid: 6637748
Machacek ME, Gogakos T, Fletcher MC, Lunderville KA, Swoboda KJ, Sohani AR. Unusual inclusions in cerebrospinal fluid macrophages of spinal muscular atrophy patients treated with nusinersen. Int J Lab Hematol. 2020. https://doi.org/10.1111/ijlh.13392 .
doi: 10.1111/ijlh.13392
pubmed: 33201586
Frazier KS. Antisense oligonucleotide therapies: the promise and the challenges from a toxicologic pathologist’s perspective. Toxicol Pathol. 2015;43:78–89. https://doi.org/10.1177/0192623314551840 .
doi: 10.1177/0192623314551840
pubmed: 25385330
Hartmann G, Krug A, Waller-Fontaine K, Endres S. Oligodeoxynucleotides enhance lipopolysaccharide-stimulated synthesis of tumor necrosis factor: dependence on phosphorothioate modification and reversal by heparin. Mol Med. 1996;2:429–38.
doi: 10.1007/BF03401902
Schoch KM, Miller TM. Antisense oligonucleotides: translation from mouse models to human neurodegenerative diseases. Neuron. 2017;94:1056–70. https://doi.org/10.1016/j.neuron.2017.04.010 .
doi: 10.1016/j.neuron.2017.04.010
pubmed: 28641106
pmcid: 5821515
Freigang M, Wurster CD, Hagenacker T, Stolte B, Weiler M, Kamm C, Schreiber-Katz O, Osmanovic A, Petri S, Kowski A, et al. Serum creatine kinase and creatinine in adult spinal muscular atrophy under nusinersen treatment. Ann Clin Transl Neurol. 2021. https://doi.org/10.1002/acn3.51340 .
doi: 10.1002/acn3.51340
pubmed: 33792208
pmcid: 8108420